Brief: Novalgen To Begin World’s First Clinical Trial For A Self-Regulating Immunotherapy
17/09/2025 14:10
Sept 17 (Reuters) - Mabion SA MABP.WA: NOVALGEN TO BEGIN WORLD’S FIRST CLINICAL TRIAL FOR A SELF-REGULATING IMMUNOTHERAPY Source text: ID:nGNX5XfHbX Further company coverage: MABP.WA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabion SA
See all newsBrief: Mabion Signs Annex To Extend Production Agreement With Novavax To End of 2029
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys